Personalized medicine is revolutionizing healthcare by tailoring treatment strategies to the unique genetic and epigenetic profiles of individuals. This research project aims to explore the intersection of pharmacogenomics and epigenetics, with a focus on the role of histone modifications in drug response variability. Histone modifications, which regulate gene expression, play a crucial role in the dynamic interplay between the genome and external factors, influencing individual responses to therapeutic agents.

Building on previous studies in pharmacogenomics, which emphasize the importance of genetic polymorphisms in predicting drug efficacy and toxicity, this project integrates cutting-edge epigenetic research to provide a more comprehensive understanding of drug responses. We hypothesize that specific patterns of histone acetylation, methylation, and other post-translational modifications contribute to the interindividual variability seen in drug metabolism and treatment outcomes.

Through a combination of high-throughput genomic sequencing and advanced epigenetic profiling, we will identify key histone modifications that correlate with altered drug responses. The project will also explore the potential for these epigenetic markers to serve as predictive biomarkers for personalized therapeutic interventions. Ultimately, this work will advance the development of personalized medicine strategies, improving patient outcomes by enabling more precise and individualized treatment plans.